TICKERNERD
Menu
CLNNCLNNConsumer Defensive · Packaged Foods

CLNN Stock Forecast: Clene, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$4.37
0.00% on the day

The 5 Wall Street analysts covering Clene, Inc. hold a median 12-month price target of $30 — +586.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 28 of 100 as at 22 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$55.5M
Ticker Nerd rank
28 / 100
Median analyst target
$30
Analysts covering
5
Total return, dividends reinvested
1W
+5.6%
1M
−25.3%
YTD
−25.6%
1Y
−18.2%
From 52W high
−65.0%
From 52W low
+11.5%
$4
$13
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CLNN stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Clene, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
28 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
92
Size
81
Momentum
70
Growth
36
Revisions
33
Value
25
Volatility
23
Issuance
11
Quality
10

Accruals (92): Reported profit is backed by cash, and the company is not expanding recklessly.

Quality (10): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CLNN stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CLNN, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$10$20$30$40$50Oct 25Jan 26Apr 26Jul 26CLNNHigh $50Median $30Low $20

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says5 analysts
5 Buy0 Hold0 Sell
Low $20Median $30High $50

The green dot is the last close — the median target sits +586.5% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
4 May 2026D. Boral CapitalMaintainsBuy$23
4 May 2026HC Wainwright & Co.ReiteratesBuy$31
13 Mar 2026Canaccord GenuityMaintainsBuy—
12 Mar 2026D. Boral CapitalMaintainsBuy—
9 Jan 2026D. Boral CapitalMaintainsBuy—
10 Dec 2025D. Boral CapitalMaintainsBuy—
3 Dec 2025D. Boral CapitalMaintainsBuy—
17 Nov 2025D. Boral CapitalMaintainsBuy—
25 Sept 2025D. Boral CapitalMaintainsBuy—
10 Sept 2025BenchmarkMaintainsBuy—
21 Aug 2025D. Boral CapitalMaintainsBuy—
18 Aug 2025Canaccord GenuityMaintainsBuy—
14 Aug 2025D. Boral CapitalMaintainsBuy—
18 July 2025D. Boral CapitalMaintainsBuy—
30 June 2025D. Boral CapitalMaintainsBuy—
8 May 2025BenchmarkMaintainsBuy—
8 May 2025D. Boral CapitalMaintainsBuy—
23 Apr 2025Jones TradingInitiatesBuy—
8 Apr 2025D. Boral CapitalMaintainsBuy—
8 Apr 2025HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CLNN appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

CLNN analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Clene, Inc. (CLNN) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−1.6×

Cheaper than 84% of US stocks

Price / sales
414.2×

Cheaper than 2% of US stocks

Price / book
−2.7×

Cheaper than 96% of US stocks

EV / EBITDA
−3.5×

Cheaper than 75% of US stocks

Growth & margins
Revenue growth (YoY)
−81.5%

Higher than 3% of US stocks

Earnings growth (YoY)
−81.5%

Higher than 4% of US stocks

Gross margin
100.0%

Higher than 99% of US stocks

Operating margin
−13740.0%

Higher than 2% of US stocks

Net margin
78.5%

Higher than 98% of US stocks

Returns & dividend
Return on equity
148.8%

Higher than 97% of US stocks

Return on assets
−56.1%

Higher than 7% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

CLNN vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelPackaged Foods
CompanyMarket capTKN rank
CLNNClene, Inc.$55.5M
28
BRIDBridgford Foods Corp.$57.0M
35
BOFBranchOut Food, Inc.$59.1M
20
BHSTBioHarvest Sciences, Inc.$45.4M
41
HAINThe Hain Celestial Group, Inc.$72.2M
45
LSFLaird Superfood, Inc.$41.5M
20
BRLSBorealis Foods, Inc.$39.7M
46

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Clene, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CLNN news & analysis

Clene Eyes Q4 NDA for ALS Drug After FDA-Requested Biomarker Analyses

MarketBeat · 19 Aug 2026positive

Clene is preparing to submit a New Drug Application seeking accelerated approval for CNM-Au8 in amyotrophic lateral sclerosis, after completing additional biomarker analyses requested by the FDA. CEO Rob Etherington confirmed the plan in an interview.

Why it matters — A CLNN watcher would care because a planned NDA submission marks a key regulatory step for the company's lead ALS candidate, CNM-Au8.

Clene to Present at the Emerging Growth Conference

GlobeNewsWire · 17 Aug 2026neutral

Clene Inc. announced that management will present at the Emerging Growth Conference, a virtual event scheduled for August 19, 2026, at 3:10 p.m. The company disclosed the date and time of the presentation.

Why it matters — A CLNN watcher would care because the company presentation offers an opportunity to hear directly from management about Clene's business and outlook.

Clene Inc. (CLNN) Reports Q2 Loss, Beats Revenue Estimates

Zacks Investment Research · 14 Aug 2026negative

Clene Inc. reported a Q2 quarterly loss of $0.60 per share, wider than the Zacks Consensus Estimate of a $0.37 loss. The latest loss was narrower than the $0.78 per share loss recorded in the same quarter a year earlier, while revenue beat estimates.

Why it matters — The results show the company missed analyst earnings expectations for the quarter despite improving year-over-year, which is relevant to investors tracking Clene's financial trajectory.

Clene Reports Second Quarter 2026 Financial Results and Recent Operating Highlights

GlobeNewsWire · 14 Aug 2026positive

Clene reported its second quarter 2026 financial results and said it expects to submit a New Drug Application for CNM-Au8 in ALS under the accelerated approval pathway in early Q4 2026, citing survival and functional benefit in patients whose NfL levels declined or stabilized.

Why it matters — A CLNN watcher would care because a planned NDA submission in early Q4 2026 represents a major regulatory milestone for the company's lead ALS candidate, CNM-Au8, under the accelerated approval pathway.

Clene Targets Early Q4 NDA Filing for CNM-Au8 in ALS

MarketBeat · 12 Aug 2026positive

Clene said it plans to file a new drug application (NDA) in early Q4 for CNM-Au8 as a treatment for amyotrophic lateral sclerosis, following a series of meetings with the U.S. Food and Drug Administration.

Why it matters — The planned NDA submission marks a key regulatory milestone for Clene's lead candidate CNM-Au8, a significant development for CLNN watchers following FDA discussions.

FAQ

Frequently asked questions about CLNN stock

What is the CLNN stock price forecast for 2026-2027?

The 5 Wall Street analysts covering Clene, Inc. have a median 12-month price target of $30, with estimates ranging from $20 to $50. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CLNN stock a buy right now?

Of the 5 analysts covering Clene, Inc., 5 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Clene, Inc. 28 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CLNN?

As at 22 Aug 2026, Clene, Inc. ranks 28 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (92 of 100).

Will CLNN stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts implies +586.5% from the last close, and Ticker Nerd's factor model ranks Clene, Inc. 28 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CLNN stock forecast for 2030?

No analyst covering Clene, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CLNN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $20 to $50 over the next 12 months.

How has CLNN stock performed over the past year?

Clene, Inc. returned -18.2% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Clene, Inc. do?

Clene Inc. is a biopharmaceutical company that focuses on the development of nanotechnology-based therapies for neurodegenerative diseases.

What is the latest news on CLNN?

The most recent item we track (MarketBeat, 19 Aug 2026): "Clene Eyes Q4 NDA for ALS Drug After FDA-Requested Biomarker Analyses". Clene is preparing to submit a New Drug Application seeking accelerated approval for CNM-Au8 in amyotrophic lateral sclerosis, after completing additional biomarker analyses requested by the FDA. CEO Rob Etherington confirmed the plan in an interview.

Company

About Clene, Inc.

Clene Inc. is a biopharmaceutical company that focuses on the development of nanotechnology-based therapies for neurodegenerative diseases. Its primary purpose is to innovate and advance treatment options for conditions such as multiple sclerosis, amyotrophic lateral sclerosis (ALS), and Parkinson's disease. Founded on the principles of using clean-surfaced, highly catalytic nanocrystals, Clene Inc. strives to enhance cellular energy production, which is crucial for neuronal health and function. This company's work is particularly significant in the medical field, impacting the biotechnology and healthcare sectors by addressing unmet medical needs with novel treatment approaches. Through various clinical trials and research initiatives, Clene Inc. aims to bring groundbreaking solutions to market, potentially altering the landscape of neurotherapeutics. Based in the United States, Clene Inc. continues to push the boundaries of scientific innovation and plays a pivotal role in the pursuit of effective therapies for chronic and debilitating neurological conditions.

CEO Mr. Robert Etherington MBA · 76 employees · United States · https://clene.com